NCT03092830

Brief Summary

The objective is to find genes which are responsible for the appearance of skin tumors (sCC, BCC) and it will be the basis for prediction of the disease and response to the treatment

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 22, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 28, 2017

Completed
1 day until next milestone

Study Start

First participant enrolled

March 29, 2017

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 7, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 7, 2020

Completed
Last Updated

April 30, 2019

Status Verified

April 1, 2019

Enrollment Period

3.4 years

First QC Date

March 22, 2017

Last Update Submit

April 28, 2019

Conditions

Squamous Cell CarcinomaBasal Cell Carcinoma

Keywords

SCCBCCDNARNAHEDGE HOGepidermal growth factor receptor

Outcome Measures

Primary Outcomes (1)

  • Molecular Characterization of cutaneous tumors

    samples from subjects

    5 years

Study Arms (1)

1-arm, 500 participates

Molecular testing of DNA/RNA from skin tumors, SCC/BCC

Genetic: Molecular testing of DNA/RNA from skin tumors, SCC/BCC

Interventions

Molecular testing of DNA/RNA from skin tumors, SCC/BCCGENETIC

Molecular testing of DNA/RNA from skin tumors, SCC/BCC

1-arm, 500 participates

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

above 18 years old with Scc and BCC skin tumors not pregnant women and no children or any person without judgment ability

You may qualify if:

  • patient that have sCC and BCC tumors
  • above 18 years old

You may not qualify if:

  • below 18 years old
  • pregnant women
  • children or person without judgment ability

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

RabinMC

Petah Tikva, 49100, Israel

RECRUITING

Related Publications (1)

  • Winder M, Viros A. Mechanisms of Drug Resistance in Melanoma. Handb Exp Pharmacol. 2018;249:91-108. doi: 10.1007/164_2017_17.

    PMID: 28275910BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

DNA or RNA which will be produced from skin biopsy specimens of SCC,BCC

MeSH Terms

Conditions

Carcinoma, Squamous CellCarcinoma, Basal Cell

Condition Hierarchy (Ancestors)

CarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNeoplasms, Squamous CellNeoplasms, Basal Cell

Study Officials

  • DR Dean Ad EL, MD

    Rabin Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

DR Dean Ad EL, MD

CONTACT

+972-3-9376366deana@clalit.org.il

DR Asaf Olshinka, MD

CONTACT

+972-3-9376366

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 22, 2017

First Posted

March 28, 2017

Study Start

March 29, 2017

Primary Completion

August 7, 2020

Study Completion

August 7, 2020

Last Updated

April 30, 2019

Record last verified: 2019-04

Data Sharing

IPD Sharing
Will not share

Locations

IL(1)